Clinical trials provide patients with relapsed or treatment-resistant lymphoma access to emerging therapies, making conversations with providers essential, according to Dr. Jennif ...

Dr. Hua-Jay Cherng, a hematologist oncologist at NewYork-Presbyterian/Columbia University Medical Center, discussed how ctDNA ...

Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and reduce chemotherapy toxicity. The development of treatments beyond ...

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...

Among the 94 evaluable patients, the overall response rate was 95.7%. The Food and Drug Administration (FDA) has granted accelerated approval to Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the ...

An exploratory analysis of the phase 2 ALYCANTE trial (NCT04531046) reveals that patients with relapsed/refractory large ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive ...

Please provide your email address to receive an email when new articles are posted on . Pre-transplant immune checkpoint inhibitors improved survival in relapsed Hodgkin lymphoma compared with ...

The big question in administration of bispecific antibodies these days is how quickly they can move to the outpatient setting ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...

Opdivo (nivolumab) has received approvals for two new indications in classical Hodgkin Lymphoma (cHL) from the US Food and ...